Literature DB >> 25337680

Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment.

Muhammad Zaeem Noman1, Yosra Messai, Jane Muret, Meriem Hasmim, Salem Chouaib.   

Abstract

Accumulating evidence indicate that the behavior of tumorigenic cells is highly influenced by their microenvironment. In this regard, microenvironmental hypoxia plays a determinant role in the emergence of CTC (circulating tumor cells) and CSC (cancer stem cells). CTCs are believed to be indicators of residual disease and thus pose an increased risk of metastasis. In spite of being rare and exposed to immune attack, these cells are capable to escape the immune system of the host. Although CTC play a pivotal role in the metastatic cascade and their prognostic impact has been repeatedly demonstrated, little is known about their escape mechanisms to immune system of the host. Therefore a better knowledge of the immunogenicity of these cells and their cross talk with immune killer cells as well as with tumor microenvironment may represent an exciting new immunotherapy opportunity. In this chapter, we will discuss how hypoxia is involved in the regulation of tumor progression and induction of EMT and cancer stem cell like features. We will also illustrate the relationship between hypoxia and CTC and review how CTC interact with the cells of immune system (both innate and adaptive) in terms of their survival and EMT phenotype. We will attempt to outline how hypoxic stress may confer resistance to CTC by giving them EMT and CSC like phenotype. Finally we will discuss whether the inhibition of hypoxic signaling pathways in different compartments of the solid tumor microenvironment will have an impact on CTC number, resistant phenotype and CTC lysis by immune effectors.

Entities:  

Year:  2014        PMID: 25337680      PMCID: PMC4275540          DOI: 10.1007/s12307-014-0157-3

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  50 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

Review 2.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

3.  IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Authors:  Karl-Johan Malmberg; Victor Levitsky; Håkan Norell; Cristina Teixeira de Matos; Mattias Carlsten; Kjell Schedvins; Hodjattallah Rabbani; Alessandro Moretta; Kalle Söderström; Jelena Levitskaya; Rolf Kiessling
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Authors:  J P Medema; J de Jong; L T Peltenburg; E M Verdegaal; A Gorter; S A Bres; K L Franken; M Hahne; J P Albar; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

5.  Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.

Authors:  Cristina Raimondi; Angela Gradilone; Giuseppe Naso; Bruno Vincenzi; Arianna Petracca; Chiara Nicolazzo; Antonella Palazzo; Rosa Saltarelli; Franco Spremberg; Enrico Cortesi; Paola Gazzaniga
Journal:  Breast Cancer Res Treat       Date:  2011-02-05       Impact factor: 4.872

6.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.

Authors:  D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.

Authors:  Sabine Wohlfart; David Sebinger; Petra Gruber; Judith Buch; Doris Polgar; Georg Krupitza; Margit Rosner; Markus Hengstschläger; Markus Raderer; Andreas Chott; Leonhard Müllauer
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Authors:  Galatea Kallergi; Maria A Papadaki; Eleni Politaki; Dimitris Mavroudis; Vassilis Georgoulias; Sophia Agelaki
Journal:  Breast Cancer Res       Date:  2011-06-10       Impact factor: 6.466

View more
  21 in total

1.  About seed and soil.

Authors:  Patrizia Paterlini-Bréchot
Journal:  Cancer Microenviron       Date:  2014-12

Review 2.  Molecular principles of metastasis: a hallmark of cancer revisited.

Authors:  Jawad Fares; Mohamad Y Fares; Hussein H Khachfe; Hamza A Salhab; Youssef Fares
Journal:  Signal Transduct Target Ther       Date:  2020-03-12

Review 3.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

4.  The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC).

Authors:  Chiara Nicolazzo; Gian Maria Busetto; Francesco Del Giudice; Isabella Sperduti; Diana Giannarelli; Angela Gradilone; Paola Gazzaniga; Ettore de Berardinis; Cristina Raimondi
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-29       Impact factor: 4.553

5.  Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition.

Authors:  Joanna Kapeleris; Juliana Müller Bark; Shanon Ranjit; Derek Richard; Ian Vela; Kenneth O'Byrne; Chamindie Punyadeera
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-06       Impact factor: 4.322

6.  Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.

Authors:  Suryatheja Ananthula; Abhilasha Sinha; Mohamed El Gassim; Simran Batth; Gailen D Marshall; Lauren H Gardner; Yoshiko Shimizu; Wael M ElShamy
Journal:  Oncotarget       Date:  2016-04-12

Review 7.  The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation.

Authors:  Drenka Trivanović; Jelena Krstić; Ivana Okić Djordjević; Slavko Mojsilović; Juan Francisco Santibanez; Diana Bugarski; Aleksandra Jauković
Journal:  Mediators Inflamm       Date:  2016-08-18       Impact factor: 4.711

8.  Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.

Authors:  Sara Jansson; Pär-Ola Bendahl; Anna-Maria Larsson; Kristina E Aaltonen; Lisa Rydén
Journal:  BMC Cancer       Date:  2016-07-08       Impact factor: 4.430

9.  Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.

Authors:  Shinichiro Kashiwagi; Gen Tsujio; Yuka Asano; Wataru Goto; Koji Takada; Katsuyuki Takahashi; Tamami Morisaki; Hisakazu Fujita; Tsutomu Takashima; Shuhei Tomita; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira
Journal:  J Transl Med       Date:  2018-03-09       Impact factor: 5.531

Review 10.  The viable circulating tumor cells with cancer stem cells feature, where is the way out?

Authors:  Y T Luo; J Cheng; X Feng; S J He; Y W Wang; Q Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.